Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash & Equivalents (2020 - 2023)

Historic Cash & Equivalents for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $466.4 million.

  • Cullinan Therapeutics' Cash & Equivalents fell 1902.78% to $466.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $466.4 million, marking a year-over-year decrease of 1902.78%. This contributed to the annual value of $156.2 million for FY2022, which is 16123.73% up from last year.
  • According to the latest figures from Q3 2023, Cullinan Therapeutics' Cash & Equivalents is $466.4 million, which was down 1902.78% from $491.8 million recorded in Q2 2023.
  • Cullinan Therapeutics' Cash & Equivalents' 5-year high stood at $611.0 million during Q2 2022, with a 5-year trough of $59.8 million in Q4 2021.
  • In the last 4 years, Cullinan Therapeutics' Cash & Equivalents had a median value of $352.8 million in 2022 and averaged $341.5 million.
  • In the last 5 years, Cullinan Therapeutics' Cash & Equivalents tumbled by 6446.21% in 2021 and then soared by 39405.68% in 2022.
  • Cullinan Therapeutics' Cash & Equivalents (Quarter) stood at $168.2 million in 2020, then tumbled by 64.46% to $59.8 million in 2021, then surged by 161.24% to $156.2 million in 2022, then soared by 198.68% to $466.4 million in 2023.
  • Its Cash & Equivalents was $466.4 million in Q3 2023, compared to $491.8 million in Q2 2023 and $390.7 million in Q1 2023.